Poniard Pharmaceuticals, Inc. (NASDAQ: PARD)

Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company, has their focus on developing and commercializing novel oncology products designed to impact the lives of people with cancer. Currently, the company’s development efforts are focused on picoplatin, a new generation of platinum chemotherapy agent that could potentially become a platform product. Poniard is studying this potential platform product in a number of cancer indications, combinations and formulations. For further information, visit the Company’s web site at www.poniard.com.